Application
FAT10 Antibody (C-term) western blot analysis in mouse liver tissue lysates (35ug/lane).This demonstrates the hFAT10 antibody detected the hFAT10 protein (arrow).Application
FAT10 Antibody (C-term) immunohistochemistry analysis in formalin fixed and paraffin embedded human stomach carcinoma followed by peroxidase conjugation of the secondary antibody and DAB staining.This data demonstrates the use of FAT10 Antibody (C-term) for immunohistochemistry. Clinical relevance has not been evaluated.Application
Confocal immunofluorescent analysis of FAT10 Antibody (C-term)(Cat#AP11316b) with HepG2 cell followed by Alexa Fluor 488-conjugated goat anti-rabbit lgG (green). DAPI was used to stain the cell nuclear (blue).| Product Name | FAT10 Antibody (C-term) |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | UBD, FAT10 |
| Clonality | Polyclonal |
|---|---|
| Isotype | Ig |
| Host Species | Rabbit |
| Tested Applications | WBIHCIF |
| WB:1:100~500 IHC |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Gene Synonyms | FAT10 |
|---|---|
| Alternative Names | UBD FAT10 |
| Molecular Weight(MW) | 18473 Da |
| Function | Ubiquitin-like protein modifier which can be covalently attached to target protein and subsequently leads to their degradation by the 26S proteasome, in a NUB1L-dependent manner Probably functions as a survival factor. Conjugation ability activated by UBA6. Promotes the expression of the proteasome subunit beta type-9 (PSMB9/LMP2). Regulates TNF-alpha-induced and LPS-mediated activation of the central mediator of innate immunity NF-kappa-B by promoting TNF-alpha-mediated proteasomal degradation of ubiquitinated-I-kappa-B-alpha. Required for TNF-alpha-induced p65 nuclear translocation in renal tubular epithelial cells (RTECs). May be involved in dendritic cell (DC) maturation, the process by which immature dendritic cells differentiate into fully competent antigen-presenting cells that initiate T-cell responses Mediates mitotic non-disjunction and chromosome instability, in long-term in vitro culture and cancers, by abbreviating mitotic phase and impairing the kinetochore localization of MAD2L1 during the prometaphase stage of the cell cycle. May be involved in the formation of aggresomes when proteasome is saturated or impaired Mediates apoptosis in a caspase-dependent manner, especially in renal epithelium and tubular cells during renal diseases such as polycystic kidney disease and Human immunodeficiency virus (HIV)- associated nephropathy (HIVAN) |
| Tissue Specificity | Constitutively expressed in mature dendritic cells and B-cells. Mostly expressed in the reticuloendothelial system (e.g. thymus, spleen), the gastrointestinal system, kidney, lung and prostate gland |
| Cellular Localization | Nucleus. Cytoplasm (By similarity). Note=Accumulates in aggresomes under proteasome inhibition conditions |
| Entrez Gene | 10537 |
|---|---|
| Nucleotide Accession | AAD52982 NP_006389.2 |
Application
FAT10 Antibody (C-term) western blot analysis in mouse liver tissue lysates (35ug/lane).This demonstrates the hFAT10 antibody detected the hFAT10 protein (arrow).
Application
FAT10 Antibody (C-term) immunohistochemistry analysis in formalin fixed and paraffin embedded human stomach carcinoma followed by peroxidase conjugation of the secondary antibody and DAB staining.This data demonstrates the use of FAT10 Antibody (C-term) for immunohistochemistry. Clinical relevance has not been evaluated.
Application
Confocal immunofluorescent analysis of FAT10 Antibody (C-term)(Cat#AP11316b) with HepG2 cell followed by Alexa Fluor 488-conjugated goat anti-rabbit lgG (green). DAPI was used to stain the cell nuclear (blue).| Application Notes | WB:1:100~500 IHC |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
